GSK

GSK

Market cap $116B

Airlines are cutting global flight schedules for April and May as Iran-driven energy disruptions elevate fuel costs and operational uncertainty. Tesla (TSLA) secured its first European approval for Full Self-Driving Supervised in the Netherlands, signaling potential for broader EU adoption.

British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped ​shrink tumors in patients with advanced, hard-to-treat cancers.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Generic versions of the drug will still be available to treat a rare genetic condition.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans further investments to add capabilities and strengthen long-term operations at the Rockville site INCHEON, South Korea and ROCKVILLE, MD., March 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.

Technical indicators for Pfizer and GSK have turned bullish.

GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript

Shore Capital has reiterated its buy recommendation on GSK PLC (LSE:GSK, NYSE:GSK) with a fair value of 2,500p, arguing the pharmaceutical group's shares are too cheap given the scale of its growth ambitions and that two of the market's main concerns about the business are beginning to fade. The broker's analyst, Dr Sean Conroy, said GSK, which has a market capitalisation of around £79 billion, trades at 14 times his 2026 earnings estimate and 12 times his 2027 forecast, a level he described as undemanding relative to peers on comparable growth.

GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.